MGRXMANGOCEUTICALS, INC.vs its industry peers
A metric-by-metric comparison of MANGOCEUTICALS, INC. against SIC 8090 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGRX본 종목 | $10M#5 | — | 0.8x#2 | 21.1x#4 | -26.0%#6 | -137.1%#6 | -3954.3%#5 | -164.8%#6 | — | — | -78.6%#3 | — |
| PGNY | $2.1B#1 | 29.6x#3 | 4.6x#5 | 1.6x#3 | 10.4%#3 | 7.7%#4 | 6.6%#3 | 12.9%#2 | 17.4%#1 | — | 26.0%#2 | — |
| VMD | $340M#2 | 24.8x#2 | 2.4x#3 | 1.3x#2 | 20.5%#1 | 35.1%#3 | 8.5%#2 | 10.7%#3 | 11.5%#2 | 6#1 | 36.7%#1 | — |
| PARK | $98M#3 | — | 3.3x#4 | — | — | — | — | 0.0%#5 | — | — | — | — |
| BRTX | $65M#4 | — | 21.6x#6 | 182.0x#5 | -10.3%#4 | -58.6%#5 | -4350.1%#6 | -470.7%#7 | -23478.3%#4 | — | -91.4%#4 | — |
| NIVF | $20560#6 | 0.0x#1 | 0.0x#1 | 0.0x#1 | -13.0%#5 | 1983.1%#1 | -226.9%#4 | 37.1%#1 | — | — | — | — |
| PFHO | — | — | — | — | 10.7%#2 | 57.0%#2 | 14.9%#1 | 10.2%#4 | 6.4%#3 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 8090). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice